Staurosporine

Key Product Details

Product Description

Staurosporine is a broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C, p^60v-src tyrosine protein kinase, protein kinase A, and CaM kinase II (IC₅₀ values are 3nM, 6 nM, 7 nM and 20 nM, respectively). Staurosporine reduces nuclear myosin heavy chain 9 phosphorylation which inhibits gastric cancer cell progression in transgenic mouse models. Staurosporine inhibits cell viability and promotes apoptosis in oral and pancreatic cancer cells. Staurosporine also enhances efficiency of lentiviral transduction of human hematopoietic stem and progenitor cells by 2-fold, induces dopaminergic axonal outgrowth in vitro and triggers mitophagy. Staurosporine has high affinity (K_d = 100 nM) for the yjdF aptamer. The riboswitch function of yjdF motif RNAs is activated by Staurosporine and leads to robust reporter gene expressions in B. subtilis.

Staurosporine synthesized to Ancillary Material Grade is also available.

Scientific Data Images for Staurosporine

Reduced viability of differentiated cardiomyocytes exposed to cardiotoxic small molecules.

The viability of differentiated cardiomyocytes was assessed using a Resazurin metabolism assay. A) Untreated cells metabolize Resazurin (Catalog # AR002) to produce resorufin, a fluorescent molecule that can be measured using a fluorometric plate reader. Resorufin fluorescence accumulated in untreated cardiomyocytes. Cells treated with the cardiotoxic small molecules Staurosporine (blue; Catalog # 1285), a non-selective protein kinase inhibitor, or Doxazosin (tan; Catalog # 2964), an alpha 1 antagonist, did not metabolize Resazurin, as shown by lack of fluorescence accumulation, indicating a loss of viability upon treatment. B) Cell morphology of untreated, Staurosporine-treated, and Doxazosin-treated cardiomyocytes was assessed by brightfield microscopy.

Product Specifications for Staurosporine

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Staurosporine

The following data is based on the product molecular weight 466.54.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 144 publications citing the usage of this product.

• Wakita Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of rapamycin signaling pathway. Neuropharmacology 2014 PMID: 24067927
• Li The yjdF riboswitch candidate regulates gene expression by binding diverse azaaromatic compounds. RNA 2016 PMID: 26843526
• Zhang Effect of protein kinase C alpha, caspase-3, and survivin on apoptosis of oral cancer cells induced by staurosporine. Acta Pharmacol.Sinica 2005 PMID: 16225760
• Malsy Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway. Eur.J.Med.Res. 2019 PMID: 30686270
• Ye Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics 2020 PMID: 32685004
• Lewis Staurosporine increases lentiviral vector transduction efficiency of human hematopoietic stem and progenitor cells. Mol.Ther.Methods Clin.Dev. 2018 PMID: 30038935
• Yanagihara Staurosporine: an effective inhibitor for Ca²⁺/calmodulin-dependent protein kinase II. J.Neurochem. 1991 PMID: 1846174
• Tamaoki Staurosporine, a potent inhibitor of phospholipid/Ca²⁺ dependent protein kinase. Biochem.Biophys.Res.Commun. 1986 PMID: 3457562
• Ruegg and Burgess Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. TiPS 1989 PMID: 2672462

Product Documents for Staurosporine